BR112015011982A8 - compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes - Google Patents
compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes Download PDFInfo
- Publication number
- BR112015011982A8 BR112015011982A8 BR112015011982A BR112015011982A BR112015011982A8 BR 112015011982 A8 BR112015011982 A8 BR 112015011982A8 BR 112015011982 A BR112015011982 A BR 112015011982A BR 112015011982 A BR112015011982 A BR 112015011982A BR 112015011982 A8 BR112015011982 A8 BR 112015011982A8
- Authority
- BR
- Brazil
- Prior art keywords
- dgat
- diacylglycerol acyltransferase
- disorders
- hyperlipoproteinemia
- fibrosis
- Prior art date
Links
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 title abstract 3
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- -1 acyl coenzyme a Chemical compound 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 230000003779 hair growth Effects 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 208000003532 hypothyroidism Diseases 0.000 abstract 1
- 230000002989 hypothyroidism Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940037128 systemic glucocorticoids Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003451 thiazide diuretic agent Substances 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000037221 weight management Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3593DE2012 | 2012-11-23 | ||
| IN750DE2013 | 2013-03-14 | ||
| IN3172DE2013 | 2013-10-25 | ||
| PCT/US2013/071376 WO2014081994A1 (en) | 2012-11-23 | 2013-11-22 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015011982A2 BR112015011982A2 (pt) | 2017-07-11 |
| BR112015011982A8 true BR112015011982A8 (pt) | 2019-10-08 |
Family
ID=50776577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015011982A BR112015011982A8 (pt) | 2012-11-23 | 2013-11-22 | compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150322082A1 (https=) |
| EP (2) | EP2922551B1 (https=) |
| JP (1) | JP6279600B2 (https=) |
| KR (1) | KR102176463B1 (https=) |
| CN (1) | CN104918620B (https=) |
| AU (1) | AU2013347843B2 (https=) |
| BR (1) | BR112015011982A8 (https=) |
| CA (1) | CA2892304C (https=) |
| CL (1) | CL2015001397A1 (https=) |
| CY (1) | CY1121426T1 (https=) |
| DK (1) | DK2922551T3 (https=) |
| EA (1) | EA031114B1 (https=) |
| ES (1) | ES2708626T3 (https=) |
| HR (1) | HRP20190099T1 (https=) |
| HU (1) | HUE042483T2 (https=) |
| IL (1) | IL238835B (https=) |
| LT (1) | LT2922551T (https=) |
| ME (1) | ME03315B (https=) |
| MX (1) | MX363484B (https=) |
| NZ (1) | NZ630436A (https=) |
| PE (1) | PE20150967A1 (https=) |
| PH (1) | PH12015501109B1 (https=) |
| PL (1) | PL2922551T3 (https=) |
| PT (1) | PT2922551T (https=) |
| RS (1) | RS58539B1 (https=) |
| SG (1) | SG11201503761WA (https=) |
| SI (1) | SI2922551T1 (https=) |
| SM (1) | SMT201900230T1 (https=) |
| UA (1) | UA115079C2 (https=) |
| WO (1) | WO2014081994A1 (https=) |
| ZA (1) | ZA201503304B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018052818A (ja) * | 2015-01-28 | 2018-04-05 | 武田薬品工業株式会社 | スルホンアミド化合物 |
| WO2018093698A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100795462B1 (ko) * | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| WO2010086820A1 (en) * | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| PT2710013T (pt) * | 2011-05-20 | 2016-09-28 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compostos novos como inibidores de diacilglicerol aciltransferas |
-
2013
- 2013-11-22 BR BR112015011982A patent/BR112015011982A8/pt active Search and Examination
- 2013-11-22 PT PT13856479T patent/PT2922551T/pt unknown
- 2013-11-22 AU AU2013347843A patent/AU2013347843B2/en not_active Ceased
- 2013-11-22 UA UAA201506216A patent/UA115079C2/uk unknown
- 2013-11-22 PL PL13856479T patent/PL2922551T3/pl unknown
- 2013-11-22 CN CN201380069807.4A patent/CN104918620B/zh not_active Expired - Fee Related
- 2013-11-22 ES ES13856479T patent/ES2708626T3/es active Active
- 2013-11-22 ME MEP-2019-14A patent/ME03315B/me unknown
- 2013-11-22 LT LTEP13856479.4T patent/LT2922551T/lt unknown
- 2013-11-22 MX MX2015006533A patent/MX363484B/es unknown
- 2013-11-22 SI SI201331321T patent/SI2922551T1/sl unknown
- 2013-11-22 HR HRP20190099TT patent/HRP20190099T1/hr unknown
- 2013-11-22 EP EP13856479.4A patent/EP2922551B1/en active Active
- 2013-11-22 EP EP18203369.6A patent/EP3492474B1/en active Active
- 2013-11-22 WO PCT/US2013/071376 patent/WO2014081994A1/en not_active Ceased
- 2013-11-22 US US14/646,403 patent/US20150322082A1/en not_active Abandoned
- 2013-11-22 KR KR1020157016270A patent/KR102176463B1/ko not_active Expired - Fee Related
- 2013-11-22 SG SG11201503761WA patent/SG11201503761WA/en unknown
- 2013-11-22 SM SM20190230T patent/SMT201900230T1/it unknown
- 2013-11-22 JP JP2015544141A patent/JP6279600B2/ja not_active Expired - Fee Related
- 2013-11-22 HU HUE13856479A patent/HUE042483T2/hu unknown
- 2013-11-22 DK DK13856479.4T patent/DK2922551T3/en active
- 2013-11-22 RS RS20190081A patent/RS58539B1/sr unknown
- 2013-11-22 EA EA201590982A patent/EA031114B1/ru unknown
- 2013-11-22 CA CA2892304A patent/CA2892304C/en not_active Expired - Fee Related
- 2013-11-22 PE PE2015000657A patent/PE20150967A1/es unknown
- 2013-11-22 NZ NZ630436A patent/NZ630436A/en not_active IP Right Cessation
-
2015
- 2015-05-12 ZA ZA2015/03304A patent/ZA201503304B/en unknown
- 2015-05-14 IL IL238835A patent/IL238835B/en active IP Right Grant
- 2015-05-19 PH PH12015501109A patent/PH12015501109B1/en unknown
- 2015-05-22 CL CL2015001397A patent/CL2015001397A1/es unknown
-
2019
- 2019-01-29 CY CY20191100120T patent/CY1121426T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013426A (es) | Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas. | |
| EP2583684A4 (en) | PEPTIDE WITH ANTIMICROBIAL OR ANTI-INFLAMMATORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THIS PEPTIDE AS AN ACTIVE AGENT | |
| BR112013031268A2 (pt) | "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição". | |
| ITTO20110627A1 (it) | Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche | |
| BR112012032579A2 (pt) | "terapia de diabetes" | |
| BR112015007083A2 (pt) | inibidores de histona demetilases | |
| BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
| BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
| BR112014019431A8 (pt) | Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses | |
| BR112016000975A8 (pt) | esteróides neuroativos, composições os compreendendo e uso dos mesmos | |
| PH12013502401A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
| BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
| WO2012066103A3 (en) | Inhibitors of apoptosis and uses thereof | |
| BR112018002115A2 (pt) | benzamidas aneladas | |
| BR112015010577A2 (pt) | compostos utilizados como inibidores da diacilglicerol aciltransferase | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| BR112015011982A8 (pt) | compostos inibidores de diacilglicerol aciltransferase, composição farmacêutica compreendendo estes e usos destes | |
| BR112015000275A2 (pt) | utilização de um extrato de mirta como agente anti-biopelícula face p. acnes | |
| EP2830649A4 (en) | LIQUID FORMULATION FROM A HIGHLY CONCENTRATED AND LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE | |
| BR112015010196A2 (pt) | métodos de tratar doença do fígado | |
| PH12013502403A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| BR112017019824A2 (pt) | compostos; composição farmacêutica; método para o tratamento profilático ou terapêutico da fibrose em um sujeito; usos de um composto; método para a prevenção, redução ou retardamento do acúmulo de gordura no fígado de um sujeito; método para a prevenção, redução ou retardamento da morte das células tubulares renais em um sujeito; e método para a restauração da arquitetura normal dos tecidos em um sujeito | |
| PL2505195T3 (pl) | Kompozycje farmaceutyczne ketoprofenu i metylosulfonylometanu do podawania miejscowego |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |